Prana Biotechnology Limited has today announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington’s disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington’s disease.

Prana Biotechnology Limited today announced that the European Medicines Agency (EMA) has published the Minutes from the April 2015 Meeting of its Committee for Orphan Medicinal Products (COMP), detailing the recommendation from the COMP that PBT2 be granted Orphan Designation in Europe. Prana announced the positive COMP recommendation on 28 April, 2015.

Prana Biotechnology is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC).

Prana Biotechnology has today announced the status of its End of Phase 2 discussions with the US Food and Drug Administration (FDA).

The results of Prana's Phase 2 trial in Huntington’s disease, Reach2HD, has been published in The Lancet Neurology, one of the world’s leading medical journals.

A new report studying Alzheimer's disease and co-authored by Professor Rudy Tanzi has been published by the respected journal Nature.

The Prana Biotechnology 2014 Annual Report summarises the Company's achievements over the past 12 months

Prana Biotechnology (ASX:PBT) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease.

Prana Biotechnology (ASX:PBT) has today provided an update on its clinical development program for Alzheimer’s disease.

Professor Ira Shoulson comments on joining Prana Biotechnology's Board of Directors.